These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19766330)

  • 21. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma.
    Inoue S; Nakao A; Harada A; Nonami T; Takagi H
    Am J Gastroenterol; 1994 Dec; 89(12):2222-6. PubMed ID: 7526679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated serum chromogranin A in patients with hepatocellular carcinoma.
    Leone N; Pellicano R; Brunello F; Rizzetto M; Ponzetto A
    Clin Exp Med; 2002 Nov; 2(3):119-23. PubMed ID: 12447608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer.
    Malaguarnera M; Cristaldi E; Cammalleri L; Colonna V; Lipari H; Capici A; Cavallaro A; Beretta M; Alessandria I; Luca S; Motta M
    Arch Gerontol Geriatr; 2009; 48(2):213-7. PubMed ID: 18329114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
    Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
    Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
    Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center.
    Huo TI; Huang YH; Lui WY; Wu JC; Lee PC; Chang FY; Lee SD
    Oncol Rep; 2004 Feb; 11(2):543-50. PubMed ID: 14719097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
    Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
    J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods.
    Nomura F; Ishijima M; Horikoshi A; Nakai T; Ohnishi K
    Am J Gastroenterol; 1996 Jul; 91(7):1380-3. PubMed ID: 8677999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.
    Hsia CY; Huo TI; Chiang SY; Lu MF; Sun CL; Wu JC; Lee PC; Chi CW; Lui WY; Lee SD
    Eur J Surg Oncol; 2007 Mar; 33(2):208-12. PubMed ID: 17140760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
    Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
    Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
    Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
    Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
    Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
    Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.
    Soresi M; Magliarisi C; Campagna P; Leto G; Bonfissuto G; Riili A; Carroccio A; Sesti R; Tripi S; Montalto G
    Anticancer Res; 2003; 23(2C):1747-53. PubMed ID: 12820452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP.
    Baek YH; Lee JH; Jang JS; Lee SW; Han JY; Jeong JS; Choi JC; Kim HY; Han SY
    Hepatogastroenterology; 2009; 56(91-92):763-7. PubMed ID: 19621698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
    Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
    Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
    Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
    Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
    Tang W; Miki K; Kokudo N; Sugawara Y; Imamura H; Minagawa M; Yuan LW; Ohnishi S; Makuuchi M
    Int J Oncol; 2003 May; 22(5):969-75. PubMed ID: 12684661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients.
    Cedrone A; Covino M; Caturelli E; Pompili M; Lorenzelli G; Villani MR; Valle D; Sperandeo M; Rapaccini GL; Gasbarrini G
    Hepatogastroenterology; 2000; 47(36):1654-8. PubMed ID: 11149026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients.
    Hiraoka A; Michitaka K; Horiike N; Hidaka S; Uehara T; Ichikawa S; Hasebe A; Miyamoto Y; Ninomiya T; Sogabe I; Ishimaru Y; Kawasaki H; Koizumi Y; Hirooka M; Yamashita Y; Abe M; Hiasa Y; Matsuura B; Onji M
    J Gastroenterol Hepatol; 2010 Feb; 25(2):403-7. PubMed ID: 19929922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.